Teva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, ...

Teva's reasonable valuation, an improving pipeline, and sales and profit growth potential are good enough reasons for those ...

Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...

PTC Therapeutics has signed an up to $2.9 billion licensing deal with Novartis AG for the U.S. company's experimental drug ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Bullfrog AI has lower revenue, but higher earnings than Teva Pharmaceutical ...

We recently published a list of 12 Best Stocks Under $25 To Invest In Right Now. In this article, we are going to take a look ...

Daiwa Securities Group Inc. lifted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 10.0% ...

Today, Benzinga's options scanner spotted 25 options trades for Teva Pharmaceutical Indus. This is not a typical pattern. The sentiment among these major traders is split, with 24% bullish and 60% ...

Last year, we took bold steps to ensure our sites were addressing antimicrobial resistance (AMR) throughout the entire ...

Teva Pharmaceutical Industries Limited’s TEVA stock has declined 10% in a month despite strong third-quarter results announced earlier this month. The company beat estimates for earnings as well ...